<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11705">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049606</url>
  </required_header>
  <id_info>
    <org_study_id>LAYLA_P4_NB</org_study_id>
    <nct_id>NCT02049606</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee</brief_title>
  <official_title>Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PMG Pharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PMG Pharm Co., Ltd</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet
      and CENATONE tablet in the treatment of osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes from the baseline in 100mm Pain VAS</measure>
    <time_frame>Baseline through week8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes rate from the baseline in 100mm Pain VAS</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in WOMAC</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in EQ-5D</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the patient self-assessed overall symptom score</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>LAYLA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug : LAYLA tablet/bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CENATONE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug : CENATONE tablet/qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAYLA tablet</intervention_name>
    <description>1 Tablet twice a day</description>
    <arm_group_label>LAYLA</arm_group_label>
    <other_name>LAYLA 405.4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CENATONE tablet</intervention_name>
    <description>2 Tablets once a day</description>
    <arm_group_label>CENATONE</arm_group_label>
    <other_name>Nabumetone 500mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥40 and ≤80 years of age

          -  Radiographic evidence of grade 1,2 or 3 osteoarthritis based on the Kellgren &amp;
             Lawrence radiographic entry criteria

          -  Stable osteoarthritis during 3 months

          -  Score of 100mm Pain VAS ≤ 80mm at screening

          -  Score of 100mm Pain VAS ≥ 40mm at baseline

          -  Written consent form voluntarily

        Exclusion Criteria:

          -  Disease of spine or other Lower limb joints that could affect fo evaluate the
             efficacy

          -  History of surgery or arthroscopy of the study joint within 6 months

          -  Trauma of study joint within 12 months

          -  Medication of constantly(more than 1 week) corticosteroid by oral within 3 months

          -  Diagnosed with psychical disorder, and taking medication

          -  Medication of intra-articular injection within 3 months

          -  Uncontrollable Hypertension patients at screening test

          -  History of upper gastrointestinal ulceration within 6 months, History of upper
             gastrointestinal bleeding within 12 months

          -  History of lower gastrointestinal bleeding within 12 months

          -  History of coronary artery bypass, systemic lupus erythematosus or mixed connective
             tissue disease

          -  Serum creatinine, ALT, AST, total bilirubin over ULN X 2.0 at screening test

          -  History of hypersensitivity of LAYLA, CENATONE or NSAIDs

          -  Participation in another clinical trials within 4 weeks

          -  Medication of constantly (more than 1 week) narcotic analgesics within 3 months

          -  Not consent about using effectual contraception method during trial

          -  Pregnant or lactating woman

          -  History of malignant tumor within 5 years

          -  Investigator's judgment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Baik Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Goo Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Jun Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong In, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Min Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahng Hoon Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Baik Kang, MD</last_name>
    <email>ossbkang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Baik Kang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Seung Baik Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Goo Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jin Goo Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Jun Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Han Jun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahng Hoon Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sahng Hoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Min Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jong Min Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong In, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yong In, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 13, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LAYLA</keyword>
  <keyword>Non-inferiority</keyword>
  <keyword>100mm pain VAS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
